StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.31 | $1.18 | -9.92% | 1.1M |
| 05-12 | $1.17 | $1.15 | -1.71% | 0.9M |
| 05-13 | $1.14 | $1.16 | +1.75% | 0.4M |
| 05-14 | $1.16 | $1.11 | -4.31% | 0.9M |
| 05-15 | $1.08 | $1.01 | -6.02% | 0.5M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for TCRX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $982.00K | $10.32M | $7.76M | $5.25M |
Operating Income | $-29.14M | $-135.81M | $-111.95M | $-74.90M |
Net Income | $-28.67M | $-129.77M | $-106.79M | $-71.08M |
EPS (Diluted) | $-0.22 | $-1.00 | $-0.82 | $-0.55 |
Total Assets | $201.99M | $228.79M | $262.23M | $298.56M |
Total Liabilities | $105.07M | $105.67M | $118.20M | $121.85M |
Cash & Equivalents | $128.06M | $152.41M | $169.51M | $169.39M |
Free Cash Flow OCF − CapEx | $-24.35M | $-139.73M | $-107.55M | $-73.66M |
Shares Outstanding | 129.91M | 129.78M | 129.75M | 129.70M |
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Fundamentals not available for TCRX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.